Introduction {#s1}
============

Anxiety disorder (AD) is a chronic disorder, highly prevalent in the adult population, with the lifetime prevalence in the general population estimated at 5% in western countries [@pone.0036370-Wittchen1], [@pone.0036370-Faravelli1]. Studies in Asia have shown an even higher lifetime prevalence [@pone.0036370-Chen1]. In a study in Taiwan, Hwu et al. [@pone.0036370-Hwu1] found that the life time prevalence of AD differed considerably according to geographic sampling area, ranging from 3.7% to 10.5%. AD often causes sleep disturbance [@pone.0036370-Papadimitriou1], and has a detrimental effect on health outcomes such as increased risk of heart disease and respiratory resistance in asthma [@pone.0036370-Roest1], [@pone.0036370-Ritz1].

In examining the relationship between AD and malignancy, most studies have focused on the issue of anxiety among patients with malignancy and found that increased anxiety is not uncommon among cancer patients [@pone.0036370-Jadoon1]--[@pone.0036370-Burgess1]. However, in this study, we explored the possibility of reverse causality, to determine whether AD is a risk or protective factor in the development of malignancy. Following a review of the literature, we found that only a limited number of papers discussed or even addressed this issue, and the association between AD and cancer remains unclear [@pone.0036370-Hamer1]--[@pone.0036370-Gross1]. Recently published meta-analysis focusing only on prospective studies uncovered the fact that psychological distress, including depression, anxiety, and poor quality of life, are associated with a statistically significant (6%) increase in the risk of cancer [@pone.0036370-Chida1].

To the best of our knowledge, no nationwide, population-based studies outlining the possible relationship between AD and cancer have been conducted in Taiwan. The aim of this study was to assess the risk of all forms of cancer among patients with AD in Taiwan. The results, presented in this paper, were generated from a retrospective cohort study of patients with AD. The original database was derived from the National Health Insurance (NHI) system in Taiwan.

Methods {#s2}
=======

Database {#s2a}
--------

This study used claims data from the National Health Insurance Research Database (NHIRD), retrospectively collected from NHI, representing health care data from \>96% of all medical claims in Taiwan since 1996. The NHI program provides comprehensive medical services, including ambulatory care, inpatient care, physical therapy, dental services, prescription drugs, medical institutions, and registration files with scrambled identifications. We obtained a representative claims dataset of a sample of one million enrollees, randomly selected from the entire insured population included in the NHI program base between 1996 and 2000. The diagnoses in the database were coded using the International Classification of Diseases 9th Revision of the Clinical Modification (ICD-9-CM). A more detailed description of the NHIRD was previously described [@pone.0036370-Lu1].

Study sample {#s2b}
------------

For the study cohort, we selected patients who had been diagnosed with AD between 1 January 2000 and 31 December 2002 (ICD-9-CM codes 300.0, 300.2, 300.3, 308.3 and 309.81). To ensure the accuracy of diagnosis of AD, we selected only subjects who had been admitted at least three times as a study cohort. We then excluded patients who had any type of cancer (ICD-9-CM codes 140--239) prior to the date of indexing. Finally, we identified a total of 24,066 patients with AD. To assemble a comparison cohort, we randomly selected 96,104 enrollees without a history of AD. These controls were matched with the study cohort at a ratio of 1∶4 on frequency of age and sex using the same exclusion criteria during the same period.

Both study cohorts were followed until a diagnosis of cancer was made, or until the time the subject was lost to follow-up, death, termination of insurance, or other causes by the end of 2008.

In addition, we also searched hypertension (ICD-9-CM codes 401--405) and diabetes mellitus (ICD-9-CM codes 150), and hyperlipidemia (ICD-9-CM codes 272) as comorbidities at the baseline.

Statistical analysis {#s2c}
--------------------

A chi-square tests were carried out to examine the differences in the distribution of socio-demographic factors and comorbidities between the cohorts with and without AD. Person-years of follow-up duration were calculated for each person until cancer was diagnosed or censored. A Poisson regression model was used to examine the incidence density rates and incidence rate ratio (IRR) and 95% confidence interval (95% CI) of cancer with categorical variables were calculated for each cohort. Multivariate Cox proportional hazard models were used to estimate hazard ratio (HR) and 95% CI for factors associated with cancer risk. We performed all analysis using the SAS statistical package (SAS System for Windows, Version 9.1) with the statistical adopted significance level at 0.05.

Results {#s3}
=======

Of the total sample of 120,170 subjects, with a mean age of 54.0 years in the non-AD cohort and 54.1 years in the AD cohort. When focused on AD group only, we found the AD cohort tended to comprise more females (64.3%) and was more likely to be younger (26.9% in 30--44 years of age). Compared to the non-AD group, the AD cohort tended to live in lower urbanized areas (28.9% in urbanization level 4 and 5), and to have hypertension (44.6% vs. 26.7%), diabetes mellitus (11.6% vs. 9.5%) and hyperlipidemia (24.7% vs. 12.9%) ([Table 1](#pone-0036370-t001){ref-type="table"}).

10.1371/journal.pone.0036370.t001

###### Baseline characteristics between anxiety disorder group and non-anxiety disorder group in 2000--2002.

![](pone.0036370.t001){#pone-0036370-t001-1}

  Variables                                    Anxiety disorder                             
  ------------------------------------------- ------------------ -------- -------- -------- ----------
  Sex                                                                                          0.86
  Women                                             61,768         64.3    15,482    64.3   
  Men                                               34,336         35.7    8,584     35.7   
  Age, years                                                                                   1.00
  30--44                                            29,292         27.0    7,323     26.9   
  45--54                                            24,764         22.8    6,191     22.8   
  55--64                                            18,029         16.6    4,524     16.6   
  ≥65                                               24,019         22.1    6,028     22.2   
  Mean (SD)[†](#nt103){ref-type="table-fn"}          54.0         (14.3)    54.1    (13.9)     0.94
  Urbanization level                                                                         \<0.0001
  1                                                 28,742         29.9    6,374     26.5   
  2                                                 27,506         28.6    6,785     28.2   
  3                                                 16,749         17.4    3,959     16.5   
  4                                                 12,966         13.5    4,020     16.7   
  5                                                 10,140         10.6    2,928     12.2   
  Co-morbidity                                                                              
  Hypertension                                      25,678         26.7    10,732    44.6    \<0.0001
  Diabetes mellitus                                 9,089          9.5     2,798     11.6    \<0.0001
  Hyperlipidemia                                    12,401         12.9    5,932     24.7    \<0.0001

Urbanization level: 1 indicate the highest level of urbanization and 5 the lowest

Chi-square test,

student T-test.

Hypertension: ICD-9-CM (A-code): 401--405 (A260 and A269), admission more than three times.

Diabetes mellitus: ICD-9-CM (A-code): 250 (A181), admission more than twice in the first year.

Hyperlipidemia: ICD-9-CM (A-code): 272 (A182), admission more than three times.

[Table 2](#pone-0036370-t002){ref-type="table"} presents a comparison of incidence density of cancer during the 9-year follow-up period for subjects with and without AD, according to socio-demographic factors and comorbidities. The incidence of cancer was slightly higher in the AD cohort than in the non-AD cohort (7.59 vs. 7.33 per 1,000 person-years), with an IRR of 1.04 (95% CI = 0.98--1.10). The IRR of cancer was highest in the youngest age group (30--44 years of age, IRR = 1.18, 95% CI = 0.99--1.40). Among the patients with hypertension, we observed that patients with AD had a lower incidence than subjects without AD (10.3 vs. 11.9 per 1,000 person-years; IRR = 0.87, 95% CI = 0.80--0.94).

10.1371/journal.pone.0036370.t002

###### Comparisons of incidence density of cancer between anxiety disorder group and non-anxiety disorder group by characteristics.

![](pone.0036370.t002){#pone-0036370-t002-2}

                        Anxiety disorder                                                       
  -------------------- ------------------ --------- ------ ------- --------- ------ ---------- ------------------------------------------------------
  All                        5,503         750,350   7.33   1,467   193,207   7.59     1.04                         (0.98--1.10)
  Sex                                                                                          
  Women                      2,994         490,473   6.10    801    126,440   6.34     1.04                         (0.96--1.12)
  Men                        2,509         259,877   9.65    666    66,767    9.97     1.03                         (0.95--1.13)
  Age, years                                                                                   
  30--44                      563          240,916   2.34    169    61,461    2.75     1.18                         (0.99--1.40)
  45--54                     1,087         204,396   5.32    290    51,421    5.64     1.06                         (0.93--1.21)
  55--64                     1,298         144,457   8.99    341    36,672    9.30     1.03                         (0.92--1.17)
  ≥65                        2,555         160,581   15.9    667    43,653    15.3     0.96                         (0.88--1.05)
  Urbanization level                                                                           
  1                          1,502         227,091   6.61    364    51,455    7.07     1.07                         (0.96--1.20)
  2                          1,562         216,528   7.21    388    54,886    7.07     0.98                         (0.88--1.10)
  3                           906          130,615   6.94    228    31,686    7.20     1.04                         (0.90--1.20)
  4                           851          99,830    8.52    269    32,156    8.37     0.98                         (0.86--1.13)
  5                           682          76,276    8.94    218    23,024    9.47     1.06                         (0.91--1.23)
  Co-morbidity                                                                                 
  Hypertension                                                                                 
   No                        3,314         565,762   5.86    609    109,651   5.55     0.95                         (0.87--1.03)
   Yes                       2,189         184,589   11.9    858    83,556    10.3   **0.87**   **(0.80--0.94)** [\*\*](#nt110){ref-type="table-fn"}
  Diabetes mellitus                                                                            
   No                        4,733         686,830   6.89   1,223   171,974   7.11     1.03                         (0.97--1.10)
   Yes                        770          63,520    12.1    244    21,232    11.5     0.95                         (0.82--1.09)
  Hyperlipidemia                                                                               
   No                        4,609         654,514   7.04   1,060   145,678   7.28     1.03                         (0.97--1.10)
   Yes                        894          95,836    9.33    407    47,528    8.56     0.92                         (0.82--1.03)

per 1,000 person-year.

IRR: incidence rate ratio.

p\<0.05,

p\<0.001.

Multivariate analysis with Cox proportional hazard regression showed that after adjusting for the urbanization level and comorbidities, patients with AD was not significantly related to the development of cancer (HR = 1.01, 95% CI = 0.95--1.07) ([Table 3](#pone-0036370-t003){ref-type="table"}).

10.1371/journal.pone.0036370.t003

###### Hazard ratios and 95% confidence interval of cancer associated with anxiety disorder in Cox\'s regression analysis in different cancer.
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                                  Percentage of cancer                    
  ------------------------------ ---------------------- ------ ---------- ----------------------------------------------------
  Overall                                 5.73           6.10     1.01                        (0.95--1.07)
  Oral cancer                             0.26           0.26     0.81                        (0.40--1.61)
  Colorectal cancer                       0.86           0.84     0.92                        (0.79--1.08)
  Liver cancer                            0.72           0.85     1.11                        (0.95--1.30)
  Lung cancer                             0.74           0.81     1.05                        (0.89--1.23)
  Breast cancer (women only)              0.98           1.16     1.32                        (0.95--1.34)
  Cervical cancer (women only)            0.35           0.25     0.72      (0.51--1.03)[\*\*](#nt114){ref-type="table-fn"}
  Prostate cancer (men only)              0.66           1.00   **1.32**   **(1.02--1.71)** [\*](#nt113){ref-type="table-fn"}
  Other cancers                           2.06           2.08     1.00                        (0.88--1.15)

ICD-9-CM: oral cancer, 140.xx--149.xx; colorectal cancer, 153.xx and 154.xx; liver cancer, 155.xx; lung cancer, 162.xx; breast cancer, 174.xx; cervical cancer, 180.xx; prostate cancer, 185.xx.

Adjusted for urbanization, hypertension, diabetes mellitus, and hyperlipidemia.

p-value\<0.05,

p-value = 0.0678.

However, further specific analysis on cancer type determined that patients with AD had a significantly higher risk of prostate cancer (HR = 1.32, 95% CI = 1.02--1.71) ([Table 3](#pone-0036370-t003){ref-type="table"}); particularly in the older age group (≥65 years; HR = 1.45, 95% CI = 1.09--1.93) ([Table 4](#pone-0036370-t004){ref-type="table"}). In addition, we also observed that the AD cohort had a significantly higher percentage than the non-AD cohort to undergo prostate specific antigen (PSA) testing, regardless of the age group (30--44 years, 7.83% vs. 2.92%; 45--54 years 32.0% vs. 12.1; 55--64 years, 46.2% vs. 25.2%; ≥65 years, 54.5% vs. 35.9%) ([Table 5](#pone-0036370-t005){ref-type="table"}). [Table 3](#pone-0036370-t003){ref-type="table"} also revealed that patients with AD had a marginally significantly lower risk to develop cervical cancer (HR = 0.72, 95% CI = 0.51--1.03), and [Table 5](#pone-0036370-t005){ref-type="table"} showed a significantly higher percentage of AD cohort to undergo Papanicolaous smear testing compared to non-AD cohort.

10.1371/journal.pone.0036370.t004

###### Multivariable Cox\'s regression analysis of cancer associated with anxiety disorder among age groups.
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                                  Percentage of cancer                    
  ------------------------------ ---------------------- ------ ---------- ----------------------------------------------------
  Prostate cancer (men only)                                              
  30--44                                  0.00           0.00      --     
  45--54                                  0.16           0.10     0.46                        (0.10--2.14)
  55--64                                  0.75           0.98     1.25                        (0.68--2.29)
  ≥65                                     1.63           2.66   **1.45**   **(1.09--1.93)** [\*](#nt116){ref-type="table-fn"}
  Cervical cancer (women only)                                            
  30--44                                  0.21           0.06     0.33                        (0.10--1.06)
  45--54                                  0.34           0.35     0.98                        (0.55--1.76)
  55--64                                  0.42           0.30     0.78                        (0.38--1.60)
  ≥65                                     0.50           0.32     0.67                        (0.35--1.28)

Adjusted for urbanization, hypertension, diabetes mellitus, and hyperlipidemia.

p\<0.05,

p\<0.001,

p\<0.0001.

10.1371/journal.pone.0036370.t005

###### The distribution of prostate specific antigen and Papanicolaous smear between anxiety disorder group and non-anxiety disorder group.
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                         Anxiety disorder                        
  --------------------- ------------------ ------ ------- ------ ----------
  PSA                                                            
  Age, year                                                      
   30--44                      294          2.92    197    7.83   \<0.0001
   45--54                      939          12.1    620    32.0   \<0.0001
   55--64                     1,546         25.2    709    46.2   \<0.0001
   ≥65                        3,730         35.9   1,417   54.5   \<0.0001
  Papanicolaous smear                                            
  Age, year                                                      
   30--44                     3,868         20.1   1,586   33.0   \<0.0001
   45--54                     3,133         18.4   1,334   31.3   \<0.0001
   55--64                     1,452         12.2    689    23.1   \<0.0001
   ≥65                        1,025         7.52    475    13.9   \<0.0001

PSA: prostate specific antigen.

chi-square test.

Discussion {#s4}
==========

In this population-based cohort study, the main finding was the lack of an association between AD and the overall risk of cancer in Taiwan; however, we obtained a number of interesting findings related to the individual risk of cancer. Males with AD 65 years old and older had a significantly higher risk of developing prostate cancer. In contrast, females with AD had a marginally significantly lower risk of developing cervical cancer.

As of 1982, cancer has been the leading cause of death among the general population in Taiwan. The age-adjusted incidence rate has increased steadily reaching 270 new cases per 100,000 in 2007 [@pone.0036370-Taiwan1]. The trend is different from Surveillance Epidemiology and End Results data, which showed that the overall incidence rates of cancer for all racial/ethnic groups combined decreased by 0.7% per year between 1999 and 2006 [@pone.0036370-Edwards1]. Because this issue remains a challenge for the public health system in Taiwan, it has come to the attention of the government, resulting in a population-based investigation regarding cancer epidemiology and preventive. The Taiwanese NHI health insurance program is a good resource providing valuable materials with which to approach populated-based studies. We recently used it to evaluate the risk of malignancy for patients with systemic lupus erythematosus, resulting in positive findings [@pone.0036370-Liang1]. The current study used a similar design in an attempt to identify a relationship between AD and the risk of cancer.

To the best of our knowledge, this is the first population-based study with a collection of 24,066 patients with AD in Taiwan. To create a control group, we randomly frequency matched each AD patient with 4 individuals from the general population without AD but in a similar age, sex, and index calendar year. To compare demographic characteristics between the two groups, our data shows that patients with AD tended to have comorbidities. This is expected because chronic illness may induce AD, and vice versa [@pone.0036370-Roest1], [@pone.0036370-Khuwaja1], [@pone.0036370-Masmoudi1]. The distribution of urbanization levels illustrated a significantly higher prevalence of AD patients living in less urbanized areas of Taiwan. This is consistent with a prior study from Taiwan, indicating that individuals living in rural areas had a higher risk of AD [@pone.0036370-Hwu1].

The potential relationship between AD and the overall risk of cancer or any individual risk of cancer is still not well-recognized. Although prior meta-analysis found a significant increase in the overall risk of cancer for patients with psychological distress [@pone.0036370-Chida1], only a non-significant 1% increase in the overall risk of cancer risk was observed in our study. With regard to the individual risk of cancer, we analyzed the most common types of cancer in Taiwan and the results show different directions for various forms of cancer. However, only prostate cancer showed a significantly different risk between AD and non-AD groups. Most previous studies have focused on psychological factors and breast cancer, and the results have been contradictory. Some studies showed an increased risk of breast cancer [@pone.0036370-Ginsberg1], [@pone.0036370-Forsen1], while such associations were not observed in other studies [@pone.0036370-Lillberg1], [@pone.0036370-Protheroe1]. Earlier meta-analysis found only a modest association between specific psychosocial factors and breast cancer, contrary to the conventional wisdom that personality and stress influence the development of breast cancer [@pone.0036370-McKenna1]. Our study showed a 32% increase in the risk of breast cancer among patients with AD; however, the difference did not reach statistical significance.

Our results show a significant increase in the risk of developing prostate cancer, particularly in the older age group. This is a novel finding not uncovered in previous studies [@pone.0036370-Chida1]. One possible reason is that patients with AD tend to check their health more regularly, and are assumed to get routine check-ups, including cancer screening more frequently than the general population. [Table 5](#pone-0036370-t005){ref-type="table"} validates our assumption showing that patients with AD consistently have significantly higher PSA rates among various age groups. This may result in an increase in the early detection of prostate cancer. The same explanation may also be implied for patients with cervical cancer. We found a marginally significant decrease (28%) in the incidence rate for invasive cervical cancer among female patients with AD. More frequent Pap smear exams could identify more patients with cervical CIS/CIN/dysplasia. CIN and CIS lesions are known to precede invasive cancer in the process of carcinogenesis for cervical cancer. Normally, these patients receive treatment before the disease progresses into invasive cancer. We did not include CIN/CIS as our end-point for cervical cancer and this could decrease the relative number of cases of invasive cervical cancer. The data from the [table 5](#pone-0036370-t005){ref-type="table"} further supports this assumption. [Table 1](#pone-0036370-t001){ref-type="table"} revealed significant difference for the distribution of urbanization levels between AD and non-AD cohorts, and people live in the areas of higher urbanization levels may have more frequently screened for cancer; however, due to the limitation of the database, it is difficult to verify from this study.

Psychological parameters could alter immune and endocrine function, and it has long been hypothesized that, through this pathway, psychosocial factors may influence the incidence of cancer [@pone.0036370-Schwarz1]. A growing body of evidence has implicated the immune system as a link between the central nervous system and the processes of disease [@pone.0036370-Cox1]. A number of researchers in this field have proven that external factors such as stress, depression, or social support have a significant influence on the immune system, which in turn influence the onset and/or the course of cancer [@pone.0036370-Reynaert1].

The strength of this study is the population-based design with its generalizability. However, one major limitation that needs to be addressed is the lack of information regarding the life style or behavior of patients in the NHI database, making it impossible to adjust for health behavior related factors such as smoking and alcohol consumption. Specific personality traits and various life events are associated with health-related behavior and lifestyle factors, e.g., smoking or unhealthy nutrition. These unhealthy habits can increase the risk of cancer [@pone.0036370-Schwarz1]; however, the relationship between health behavior and AD remains controversial [@pone.0036370-Morissette1], [@pone.0036370-Morissette2].

In conclusion, this population-based retrospective cohort study identified a significant increase in the incidence of prostate cancer risk and a marginally significant decrease in the risk of cervical cancer among Taiwanese patients with AD. The intrinsic characteristic of patients with AD cause them to seek cancer screening more frequently, and this fact contributes to the results. The findings in this study may remind the NHI of Taiwan to reconsider policy regarding follow-up and cancer screening in patients with AD.
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